Secukinumab in plaque psoriasis—results of two phase 3 trials
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. METHODS: In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis) and FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis), we randomly assigned 738 patients (in the ERASURE study) and 1306 patients (in the FIXTURE study) to subcutaneous secukinumab at a dose of 300 mg or 150 mg (administered once weekly for 5 weeks, then every 4 weeks), placebo, or (in the FIXTURE study only) etanercept at a dose of 50 mg (administered twice weekly for 12 weeks, then once weekly). The objective of each study was to show the superiority of secukinumab over placebo at week 12 with respect to the proportion of patients who had a reduction of 75% or more from baseline in the psoriasis area-and-severity index score (PASI 75) and a score of 0 (clear) or 1 (almost clear) on a 5-point modified investigator's global assessment (coprimary end points). RESULTS: The proportion of patients who met the criterion for PASI 75 at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 81.6% with 300 mg of secukinumab, 71.6% with 150 mg of secukinumab, and 4.5% with placebo; in the FIXTURE study, the rates were 77.1% with 300 mg of secukinumab, 67.0% with 150 mg of secukinumab, 44.0% with etanercept, and 4.9% with placebo (P<0.001 for each secukinumab dose vs. comparators). The proportion of patients with a response of 0 or 1 on the modified investigator's global assessment at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 65.3% with 300 mg of secukinumab, 51.2% with 150 mg of secukinumab, and 2.4% with placebo; in the FIXTURE study, the rates were 62.5% with 300 mg of secukinumab, 51.1% with 150 mg of secukinumab, 27.2% with etanercept, and 2.8% with placebo (P<0.001 for each secukinumab dose vs. comparators). The rates of infection were higher with secukinumab than with placebo in both studies and were similar to those with etanercept. CONCLUSIONS: Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target. (Funded by Novartis Pharmaceuticals; ERASURE and FIXTURE ClinicalTrials.gov numbers, NCT01365455 and NCT01358578, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An Ab targeting IL-17 (secukinumab) was approved in 2016 to treat moderate-severe plaque psoriasis [54].”
From The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney (2016) · cites this paper as [54]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265
Pathogenesis and clinical features of psoriasis
Griffiths, C. E., & Barker, J. N. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61128-3 · Cited by 2,158
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., et al. (2011) · Science · doi:10.1126/science.1200439 · Cited by 1,056
Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation
Cai, Y., Shen, X., Ding, C., Qi, C., Li, K., Li, X., Jala, V. R., Zhang, H.-G., Wang, T., Zheng, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.08.001 · Cited by 1,026
Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
Lin, A. M., Rubin, C. J., Khandpur, R., Wang, J. Y., Riblett, M., Yalavarthi, S., Villanueva, E. C., Shah, P., Kaplan, M. J., & Bruce, A. T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100123 · Cited by 906
Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease
Onishi, R. M., & Gaffen, S. L. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03240.x · Cited by 894
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 859
Harper, E. G., Guo, C., Rizzo, H., Lillis, J. V., Kurtz, S. E., Skorcheva, I., Purdy, D., Fitch, E., Iordanov, M., & Blauvelt, A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.65 · Cited by 508
Cited by
Items 701–800 of 1,001
Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus
Athanassiou, P., & Athanassiou, L. (2023) · Life · doi:10.3390/life13071496 · Cited by 51
Gerdes, S., Staubach, P., Dirschka, T., Wetzel, D., Weirich, O., Niesmann, J., Mota, R., Rothhaar, A., Ardabili, M., Vlasitz, G., et al. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad186 · Cited by 33
“,16–19 The safety profile of izokibep compares favourably with anti-IL-17 monoclonal antibodies, particularly with respect to candidiasis and IBD.”
BackgroundDatta‐Mannan, A., Regev, A., Coutant, D. E., Dropsey, A. J., Foster, J., Jones, S. B., Poorbaugh, J., Schmitz, C., Wang, E., & Woodman, M. E. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3185 · Cited by 36
EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis
Pickard, A. S., Gooderham, M., Hartz, S., & Nicolay, C. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1219359 · Cited by 33
Strober, B. E., Gottlieb, A. B., Sherif, B. N., Mollon, P., Gilloteau, I., McLeod, L., Fox, T., Mordin, M., Gnanasakthy, A., Papavassilis, C., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.11.043 · Cited by 34
Secukinumab in The Treatment of Psoriasis: An Update
Reszke, R., & Szepietowski, J. C. (2017) · Immunotherapy · doi:10.2217/imt-2016-0128 · Cited by 34
Wu, N., Hsu, C., Sun, F., & Tsai, T. (2017) · The Journal of Dermatology · doi:10.1111/1346-8138.13900 · Cited by 33
Successful use of secukinumab in a 4-year-old patient with deficiency of interleukin-36 antagonist
Köstner, K., Prelog, M., Almanzar, G., Fesq, H., Haas, J., & Hügle, B. (2018) · Lara D. Veeken · doi:10.1093/rheumatology/kex510 · Cited by 33
Antipsoriatic potential of Annona squamosa seed oil: An in vitro and in vivo evaluation
Bhoir, S. S., Vishwapathi, V., & Singh, K. K. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.07.003 · Cited by 36
Discovery of Second Generation RORγ Inhibitors Composed of an Azole Scaffold
Kotoku, M., Maeba, T., Fujioka, S., Yokota, M., Seki, N., Ito, K., Suwa, Y., Ikenogami, T., Hirata, K., Hase, Y., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01567 · Cited by 34
Shimizu, T., Kamata, M., Fukaya, S., Hayashi, K., Fukuyasu, A., Tanaka, T. L., Ishikawa, T., Ohnishi, T., & Tada, Y. (2019) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2019.07.006 · Cited by 37
Rahman, P., Ritchlin, C. T., Helliwell, P., Boehncke, W., Mease, P. J., Gottlieb, A. B., Kafka, S. P., Kollmeier, A. P., Hsia, E. C., Xu, X. L., et al. (2021) · The Journal of Rheumatology · doi:10.3899/jrheum.201532 · Cited by 32
IL‐17 in intervertebral disc degeneration: Mechanistic insights and therapeutic implications
Tan, J., Li, Z., Liu, L., Liu, H., & Xue, J. (2022) · Cell Biology International · doi:10.1002/cbin.11767 · Cited by 34
“TRAF6 can also trigger the transcription of target genes by activating the mitogen‐activated protein kinase (MAPK)/activator protein 1 and CCAAT/enhancer‐binding protein pathways (Lee et al., 2011; J. K. Li et al., 2016).”
BackgroundGordon, K. B., Langley, R. G. B., Warren, R. B., Okubo, Y., Rosmarin, D. M., Lebwohl, M., Peterson, L., Madden, C., Cuyper, D. D., Davies, O. R., et al. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad429 · Cited by 35
Self-citationPsoriatic arthritis: tissue-directed inflammation?
Cafaro, G., & McInnes, I. B. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4012-7 · Cited by 33
on behalf of the FUTURE 2 Study Group, McInnes, I. B., Mease, P. J., Schett, G. A., Kirkham, B. W., Strand, V., Williams, N., Fox, T., Pricop, L., Jugl, S. M., et al. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1610-3 · Cited by 33
“Secukinumab, a fully human monoclonal antibody (mAb) that selectively neutralizes interleukin (IL)-17A, has been shown to have significant efficacy in the treatment of moderate-to-severe psoriasis and active PsA, demonstrating rapid onset of action and sustained responses with a consistent safety profile [13, 14].”
BackgroundResolution of inflammation: from basic concepts to clinical application
Neurath, M. F. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00771-2 · Cited by 40
Papp, K. A., Warren, R. B., Green, L., Reich, K., Langley, R. G. B., Paul, C. F., Asahina, A., Johnson, L., Arora, V., Osuntokun, O. O., et al. (2023) · The Lancet Rheumatology · doi:10.1016/s2665-9913(23)00120-0 · Cited by 39
Self-citationLi, Y., He, Y., Yang, F., Liang, R., Xu, W., Li, Y., Cheng, J., Liang, B., Tang, M., Shi, X., et al. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljae179 · Cited by 37
Xu, G., Xia, M., Jiang, C., Yu, Y., Wang, G., Yuan, J., & Duan, X. (2018) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2018.12.006 · Cited by 33
Feldman, S. R., Régnier, S. A., Chirilov, A., Hey, F., Gilloteau, I., & Cella, D. F. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.01.039 · Cited by 32
Reich, K., Blauvelt, A., Armstrong, A. W., Langley, R. G. B., de Vera, A., Kolbinger, F., Spindeldreher, S., Ren, M., & Bruin, G. J. M. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15637 · Cited by 32
Self-citationBruin, G. J. M., Hockey, H., Stella, P. L., Sigurgeirsson, B., Fu, R., Patekar, M., Charef, P., Woessner, R., & Boutouyrie‐Dumont, B. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14155 · Cited by 36
“dose in psoriasis phase 3 studies, showed superior results in comparison to 150 mg and is the therapeutic dose level in psoriasis patients.(4) This 300-mg single dose was known to be safe and well tolerated in previous healthy volunteer studies.”
ResultFang, H., Chen, L., & Knight, J. C. (2019) · The Lancet Rheumatology · doi:10.1016/s2665-9913(19)30134-1 · Cited by 34
Update on Cardiovascular Risk and Obesity in Psoriatic Arthritis
Ramírez, J., Azuaga-Piñango, A. B., Celis, R., & Cañete, J. D. D. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.742713 · Cited by 33
No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis
Bokor‐Billmann, T., & Schäkel, K. (2018) · Journal of Dermatological Treatment · doi:10.1080/09546634.2018.1506081 · Cited by 33
Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management
Bilal, H., Khan, M. N., Khan, S., Fang, W., Chang, W., Yin, B., Song, N., Liu, Z., Zhang, D., Yao, F., et al. (2023) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2023.2265664 · Cited by 42
“%) patients receiving secukinumab 150 mg and 300 mg, respectively, developed candidiasis (Langley et al. 2014).”
BackgroundInfluentialde Carvalho, A. V. E., Duquia, R. P., Horta, B. L., & Bonamigo, R. R. (2016) · Drugs in R&D · doi:10.1007/s40268-016-0152-x · Cited by 38
Successful treatment of type II pityriasis rubra pilaris with secukinumab
Gauci, M.-L., Jachiet, M., Gottlieb, J., Madelaine‐Chambrin, I., Rybojad, M., Bagot, M., & Bouaziz, J. (2016) · JAAD Case Reports · doi:10.1016/j.jdcr.2016.09.006 · Cited by 31
Gupta, P. K., Wagner, S. R., Wu, Q., & Shilling, R. A. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0154oc · Cited by 35
Mechanisms, impact and prevention of pathological bone regeneration in spondyloarthritis
Neerinckx, B., & Lories, R. J. U. (2017) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000404 · Cited by 31
Noguchi, M., Nomura, A., Murase, K., Doi, S., Yamaguchi, K., Hirata, K., Shiozaki, M., Hirashima, S., Kotoku, M., Yamaguchi, T., et al. (2017) · Genes to Cells · doi:10.1111/gtc.12494 · Cited by 37
“Humanized monoclonal antibodies against IL-17 have shown significant efficacies in psoriasis and psoriatic arthritis in human clinical trials (Langley et al. 2014; Communicated by: Toshio Hakoshima *Correspondence: masato.noguchi@jt.com (MN) or tsuyoshi.adachi@jt.com (TA) †These authors contributed…”
BackgroundTreatment of inflammatory bowel disease from the immunological perspective
Nakase, H. (2020) · Immunological Medicine · doi:10.1080/25785826.2020.1751934 · Cited by 32
Belinchón, I., Daudén, E., Ferrándiz, C., González‐Cantero, Á., Carrascosa, J. M., & on behalf of The Psoriasis Group of the Spanish Academy of Dermatology and Venereology (2021) · Journal of Dermatological Treatment · doi:10.1080/09546634.2021.1890683 · Cited by 36
“In the first one the PASI 100 is not mentioned, and in the CPG of biologic therapies, there is a description of the PASI 100 response rate from different RCTs of biologics (37,44,57,71,93,94).”
BackgroundThe Role of Interleukin-17 in Juvenile Idiopathic Arthritis: From Pathogenesis to Treatment
Paroli, M., Spadea, L., Caccavale, R., Spadea, L., Paroli, M. P., & Nante, N. (2022) · Medicina · doi:10.3390/medicina58111552 · Cited by 39
“The first demonstration of the role of IL-17 in human pathology was provided by the observation that monoclonal antibodies specific to IL-17A were highly effective in the therapy of psoriasis, a skin pathological condition characterized by dysregulated IL-17A production [68].”
BackgroundNeuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications
Bittner, S., & Wiendl, H. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0405-3 · Cited by 35
“In psoriasis, it showed convincing results in a phase II trial in 404 patients and 2 phase III trials in > 2000 patients [137, 138], leading to its approval in 2015; however, it failed to show efficacy in a phase II trial in refractive rheumatoid arthritis (RA) [139].”
BackgroundIL ‐17A promotes the invasion–metastasis cascade via the AKT pathway in hepatocellular carcinoma
Xu, Q., Yu, J., Guo, X., Hou, G., Yuan, S., Yang, Y., Yang, Y., Liu, H., Pan, Z., Yang, F., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12306 · Cited by 31
“…HCC growth and metastasis in vivo To assess the efficacy of IL-17A targeting therapeutics in preventing HCC progression, we administered secukinumab (Langley et al., 2014), an anti-human IL-17A monoclonal antibody approved for several inflammatory disorders, to treat an orthotopic implantation Fig.”
BackgroundMethodInfluentialIxekizumab or secukinumab in psoriasis: what difference does it make?
Paul, C. F. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16497 · Cited by 31
Deodhar, A. A., Gladman, D. D., McInnes, I. B., Spindeldreher, S., Martin, R., Pricop, L., Porter, B. O., Safi, J., Shete, A., & Bruin, G. J. M. (2019) · The Journal of Rheumatology · doi:10.3899/jrheum.190116 · Cited by 32
“Secukinumab, a fully human anti– interleukin-17A monoclonal antibody (mAb), has shown efficacy in the treatment of moderate to severe plaque psoriasis,(5-8) PsA,(9-11) and AS,(12-15) demonstrating a rapid onset of action and sustained responses with a favorable safety profile.”
BackgroundNatoli, V., Charras, A., Hofmann, S. R., Northey, S. J., Ruß, S., Schulze, F., McCann, L. J., Abraham, S., & Hedrich, C. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1245876 · Cited by 33
Taiwanese Dermatological Association consensus statement on management of psoriasis
Tsai, T., Lee, C., Huang, Y., Chi, C., Chang, Y.-T., Wong, T., Yang, C., & Wang, L. (2017) · Dermatologica Sinica · doi:10.1016/j.dsi.2017.01.002 · Cited by 30
Wei, J. C., Baeten, D., Sieper, J., Deodhar, A. A., Bhosekar, V., Martin, R., & Porter, B. O. (2017) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13094 · Cited by 30
Georgakopoulos, J. R., Ighani, A., Zhou, L. L., & Yeung, J. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14468 · Cited by 30
Chamoun, M. N., Blumenthal, A., Sullivan, M. J., Schembri, M. A., & Ulett, G. C. (2018) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2018.1426556 · Cited by 32
“The first IL-17A inhibitors, Secukinumab and Ixekizumab, were registered between 2015 and 2016 (Langley et al. 2014; Sanford and McKeage 2015; Gordon et al. 2016); these anti-IL-17 agents have been used successfully to treat ankylosing spondylitis (Baeten et al. 2013) and psoriasis (Leonardi et al.…”
BackgroundTildrakizumab for the treatment of psoriasis
Sinclair, R. D., & Palanivelu, V. T. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1544493 · Cited by 30
“chronic mucocutaneous candidiasis or discontinuation of the study drug, and all resolved on their own or with standard therapy [19].”
BackgroundThaçi, D., Körber, A., von Kiedrowski, R., Bachhuber, T., Melzer, N., Kasparek, T., Dütting, E. D., Krähn‐Senftleben, G., Amon, U., & Augustin, M. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15962 · Cited by 30
Wright, S., Alloo, A., Strunk, A., & Garg, A. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.04.010 · Cited by 32
Interleukin‐33 alleviates psoriatic inflammation by suppressing the T helper type 17 immune response
Chen, Z., Hu, Y., Gong, Y., Zhang, X., Cui, L., Chen, R., Yu, Y., Yu, Q., Chen, Y., Diao, H., et al. (2020) · Immunology · doi:10.1111/imm.13203 · Cited by 33
Current insights and future prospects for the pathogenesis and treatment for rheumatoid arthritis
Koga, T., Kawakami, A., & Tsokos, G. C. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108680 · Cited by 34
Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers
Groen, S. S., Sinkevičiūtė, D., Bay‐Jensen, A., Thudium, C. S., Karsdal, M. A., Thomsen, S. F., Schett, G. A., & Nielsen, S. H. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102760 · Cited by 35
Recent Updates in Juvenile Spondyloarthritis
Srinivasalu, H., Sikora, K. A., & Colbert, R. A. (2021) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2021.07.001 · Cited by 35
Kutwin, M., Migdalska‐Sęk, M., Brzeziańska‐Lasota, E., Zelga, P. J., & Woźniacka, A. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245834 · Cited by 35
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
Al‐Janabi, A., & Yiu, Z. Z. N. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 30
Vernero, M., Astegiano, M., & Ribaldone, D. G. (2018) · The American Journal of Gastroenterology · doi:10.1038/s41395-018-0422-z · Cited by 30
“Moreover, during secukinumab clinical trials on psoriasis 3 ulcerative colitis (UC) and 1 Crohn’s disease (CD) were reported among treatment group (whereas in the placebo group no cases of IBD were detected) (5).”
BackgroundIL-17 Signaling Triggers Degradation of the Constitutive NF-κB Inhibitor ABIN-1
Cruz, J. A., Childs, E. E., Amatya, N., Garg, A. V., Beyaert, R., Kane, L. P., Aneskievich, B. J., Ma, A., & Gaffen, S. L. (2017) · ImmunoHorizons · doi:10.4049/immunohorizons.1700035 · Cited by 29
Inborn Errors in Immunity: Unique Natural Models to Dissect Oral Immunity
Moutsopoulos, N. M., Lionakis, M. S., & Hajishengallis, G. (2015) · Journal of Dental Research · doi:10.1177/0022034515583533 · Cited by 30
Armstrong, A. W., Betts, K. A., Signorovitch, J., Sundaram, M., Li, J., Ganguli, A. X., & Wu, E. Q. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1457516 · Cited by 31
Shen, F., Verma, A. H., Volk, A. L., Jones, B. H., Coleman, B. M., Loza, M. J., Malaviya, R., Moore, B. A., Weinstock, D., Elloso, M. M., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801436 · Cited by 33
Fungal Infections Potentiated by Biologics
Davis, M. R., Thompson, G. R., & Patterson, T. F. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.02.010 · Cited by 33
Derakhshan, M. H., Dean, L. E., Jones, G. T., Siebert, S., & Gaffney, K. (2020) · RMD Open · doi:10.1136/rmdopen-2020-001206 · Cited by 33
“37 38 It should be noted that to-date no head-to-head studies of biologics have been reported in axSpA, so data from observational studies will be required to help address these questions.”
Targeting the CCR6/CCL20 Axis in Entheseal and Cutaneous Inflammation
Shi, Z., Melchor, E. G., Wu, X., Getschman, A. E., Nguyen, M., Rowland, D. J., Wilson, M., Sunzini, F., Akbar, M., Huynh, M., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41882 · Cited by 33
“Utilizing an interleukin- 23 minicircle DNA (IL- 23 MC) mouse model exhibiting key features of both PsO and PsA, we investigated CCR6 and CCL20 expression as well as the preventive and therapeutic effect of CCL20 blockade.”
BackgroundResultInfluentialDesigning drugs that combat kidney damage
Ramos, A. M., González‐Guerrero, C., Sanz, A. B., Sánchez-Niño, M. D., Rodríguez-Osorio, L., Martín-Cleary, C., Fernández‐Fernández, B., Ruiz‐Ortega, M., & Ortíz, A. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1033394 · Cited by 31
Ghazawi, F. M., Mahmood, F., Kircik, L., Poulin, Y. P., Bourcier, M., Vender, R. B., Wiseman, M., Lynde, C. W., & Litvinov, I. V. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.702776 · Cited by 32
“FIXTURE (135) 3 Secukinumab 150 mg–weeks 0–4 then every 4 weeks thereafter 12 327 45.”
BackgroundInfluentialInterventions in cytokine signaling: novel horizons for psoriasis treatment
Li, L., Liu, J., Lu, J., Wu, J., Zhang, X., Ma, T., Wu, X., Zhu, Q., Chen, Z., & Tai, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1573905 · Cited by 39
“Secukinumab speci fi cally targets IL-17A epitopes, acts quickly, is well-tolerated with few side effects, and minimizes anti-drug antibody production (206, 207).”
Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
Hanley, T., & Yiu, Z. Z. N. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s111107 · Cited by 30
“The FIXTURE and ERASURE trials reported no suicide attempts with patients on secukinumab.(28) Given these findings, close monitoring will be required to ascertain the real risk of treatment emergent depression and suicide.”
BackgroundMomose, M., Asahina, A., Umezawa, Y., & Nakagawa, H. (2017) · The Journal of Dermatology · doi:10.1111/1346-8138.14145 · Cited by 28
Warren, R. B., Barker, J., Finlay, A. Y., Burden, A. D., Kirby, B., Armendáriz, Y., Williams, R., Hatchard, C., Khare, S., & Griffiths, C. E. M. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18623 · Cited by 28
Nakajima, R., Oono, H., Sugiyama, S., Matsueda, Y., Ida, T., Kakuda, S., Hirata, J., Baba, A., Makino, A., Matsuyama, R., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00649 · Cited by 31
Aguilar-Flores, C., Castro-Escamilla, O., Ortega-Rocha, E. M., Maldonado-García, C. A., Cruz, F. J., Pérez‐Montesinos, G., Lemini-López, A., & Bonifaz, L. C. (2020) · Mediators of Inflammation · doi:10.1155/2020/8065147 · Cited by 33
He, R.-R., Wu, S., Gao, R., Chen, J., Peng, Q., Hu, H., Zhu, L., Du, Y., Sun, W., Ma, X., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001223 · Cited by 29
Galluzzo, M., Caldarola, G., SIMONE, C. D., Bernardini, N., Moretta, G., Pallotta, S., Botti, E., Campione, E., Pirrò, F., Potenza, C., et al. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1941862 · Cited by 30
Pinter, A., Schwarz, P. E. H., Gerdes, S., Simon, J. C., Saalbach, A., Rush, J. S., Melzer, N., Kramps, T., Häberle, B. M., & Reinhardt, M. (2021) · Nutrients · doi:10.3390/nu13093015 · Cited by 28
“The adverse event profile of secukinumab is well established for the approved dose [30].”
BackgroundSmad7 positively regulates keratinocyte proliferation in psoriasis
Fusco, D. D., Laudisi, F., Dinallo, V., Monteleone, I., Grazia, A. D., Marafini, I., Troncone, E., Colantoni, A., Ortenzi, A., Stolfi, C., et al. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15703 · Cited by 31
Augustin, M., Daudén, E., Mrowietz, U., Konstantinou, M. P., Gerdes, S., Kingo, K., Szepietowski, J. C., Perrot, J., Cuccia, A., Rissler, M., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16632 · Cited by 28
Atopic Dermatitis and Psoriasis: Similarities and Differences in Metabolism and Microbiome
Chen, Y., Peng, C., Zhu, L., Wang, J., Cao, Q., Chen, X., & Li, J. (2024) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-024-08995-3 · Cited by 30
“Selective biologics targeting these two inflammatory conditions, such as dupilumab and secukinumab, have demonstrated an effective role in clinical treatment of moderate to severe AD and psoriasis, respectively [12, 13].”
A Case of Granuloma Annulare Associated with Secukinumab Use
Bonomo, L., Ghoneim, S., & Levitt, J. O. (2017) · Case Reports in Dermatological Medicine · doi:10.1155/2017/5918708 · Cited by 27
Erythrodermic psoriasis and secukinumab: Our clinical experience
Mateu‐Puchades, A., Alarcón, S. S., Martorell, A., Pujol‐Marco, C., & Sánchez‐Carazo, J. L. (2018) · Dermatologic Therapy · doi:10.1111/dth.12607 · Cited by 27
“Secukinumab, is a human IgG1j monoclonal antibody that binds to the protein interleukin (IL)-17A, and is indicated in the systemic treatment of patients with psoriasis (Langley et al., 2014).”
BackgroundResultStrober, B. E., Germino, R., Guana, A., Greenberg, J. D., Litman, H. J., Guo, N., & Lebwohl, M. (2019) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1603361 · Cited by 29
Marzo‐Ortega, H., Sieper, J., Kivitz, A., Blanco, R., Cohen, M., Pavelká, K., Delicha, E. M., Stefanska, A., Richards, H. B., & Rohrer, S. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30066-7 · Cited by 27
Brüner, M., Dige, A. K., Loft, A. G., Laurberg, T. B., Agnholt, J. S., Clemmensen, K., McInnes, I. B., Lories, R. J. U., Iversen, L., Hjuler, K. F., et al. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102731 · Cited by 28
Xu, S., Gao, X., Deng, J., Yang, J., & Pan, F. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14308 · Cited by 35
Mercan, A., Uzun, S. T., Keleş, S., Hacıbeyoğlu, G., Yılmaz, R., & Reıslı, R. (2021) · The Korean journal of pain · doi:10.3344/kjp.2021.34.4.463 · Cited by 33
“It may be an alternative for preventing chronic neuropathic pain in the future [30].”
BackgroundAugustin, M., Sator, P.-G., von Kiedrowski, R., Conrad, C., Rigopoulos, D., Romanelli, M., Ghislain, P. D., Torres, T. R., Ioannides, D., Aassi, M., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18329 · Cited by 27
Pathogenesis-oriented therapy of psoriasis using biologics
Boehncke, W., & Brembilla, N. C. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2100219 · Cited by 32
“The IL-17A inhibitor secukinumab sparked the discussion around ‘clear skin’ as new therapeutic objective, yielding around 60% of PASI90 responses and 30% of PASI100 responses at the end of the induction phase (12 weeks) [79].”
BackgroundIxekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis
Blauvelt, A. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1132695 · Cited by 30
“and 76–82% for secukinumab [9,14] (Table 1).”
BackgroundInfluentialKircik, L., Fowler, J. F., Weiss, J., Meng, X., Guana, A., & Nyirady, J. (2016) · Dermatology and Therapy · doi:10.1007/s13555-016-0139-0 · Cited by 27
Feldman, S. R., Green, L., Kimball, A. B., Siu, K., Zhao, Y., Herrera, V., Nyirady, J., & Alexis, A. F. (2017) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1329502 · Cited by 29
“Secukinumab is effective in treating moderate-to-severe plaque psoriasis (16,25,26).”
BackgroundThe impact of biologic agents on health-related quality of life outcomes in patients with psoriasis
Frieder, J., Kivelevitch, D. N., Fiore, C. T., Saad, S. S., & Menter, A. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1401468 · Cited by 59
“Data from two pivotal phase III trials, ERASURE and FIXTURE, reveal superiority of secukinumab (300 and 150 mg) to etanercept (50 mg) and placebo in regard to HRQoL measures [89].”
BackgroundMethodAugustin, M., McBride, D., Gilloteau, I., O'Neill, C., Neidhardt, K., & Graham, C. N. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15047 · Cited by 27
Zozaya, N., Martínez-Galdeano, L., Alcalá, B., Hita, J. C. A., Carmona, C., Carrascosa, J. M., Herranz, P., Lamas, M. J., Trapero‐Bertran, M., & Hidalgo‐Vega, Á. (2018) · BioDrugs · doi:10.1007/s40259-018-0284-3 · Cited by 27
“Concerning tolerability, secukinumab had an acceptable safety profile, with similar adverse events than other biologic drugs indicated for psoriasis [44, 45].”
BackgroundIL-17 inhibition in axial spondyloarthritis: current and future perspectives
Torğutalp, M., & Poddubnyy, D. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1605352 · Cited by 30
“Secukinumab is a recombinant, fully human, immunoglobulin G (IgG)1 kappa monoclonal antibody that selectively binds to IL-17A, and shows the anti-inflammatory effects on target cells in synovium, entheses, and skin [46,47].”
BackgroundVaher, H., Laanesoo, A., Runnel, T., Raam, L., Prans, E., Maslovskaja, J., Abram, K., Kaldvee, B., Mrowietz, U., Weidinger, S., et al. (2019) · Experimental Dermatology · doi:10.1111/exd.14049 · Cited by 30
Macrocyclization strategy for improving candidate profiles in medicinal chemistry
Darlami, O., Pun, R., Ahn, S., Kim, S., & Shin, D. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116501 · Cited by 30
European Guideline on Chronic Pruritus. In cooperation with the European Dermatology Forum (EDF)
Weißhaar, E., Müller, S., Szepietowski, J. C., Dalgard, F. J., Garcovich, S., Kupfer, J. P., Giménez‐Arnau, A. M., Lambert, J. R., Mettang, T., Misery, L., et al. (2025) · Acta Dermato Venereologica · doi:10.2340/actadv.v105.44220 · Cited by 39
Profile of secukinumab in the treatment of psoriasis: current perspectives
Chiu, M. W., Madkan, V. K., & Roman, M. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s79053 · Cited by 31
“With regards to patient-reported outcomes, 39% of patients across two multicenter, randomized, double-blind, placebo-controlled trials chose to participate in the Psoriasis Symptom Diary.”
InfluentialSecukinumab (AIN457) in the treatment of ankylosing spondylitis
Braun, J., Baraliakos, X., & Kiltz, U. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1167183 · Cited by 29
“Based on evidence from the secukinumab psoriasis clinical development program which included pooled data from 3430 patients across 10 Phase 2 and 3 studies, amounting to 2725 patient-years of exposure, secukinumab has an acceptable safety profile that is comparable with etanercept and ustekinumab.[25,26,94,95]”
BackgroundMeta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis
Ryoo, J. Y., Yang, H., Ji, E., & Yoo, B. K. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028015626545 · Cited by 26
“Particularly, FIXTURE was designed by double-dummy protocol and included active-controlled arm with etanercept.(17-19) Patients assigned to placebo were rerandomized to secukinumab 150 or 300 mg if the psoriasis area and severity index (PASI) score measured at week 12 showed <75% improvement from baseline.”
MethodAdsit, S., Zaldivar, E. R., Sofen, H. L., Dei‐Cas, I., Maldonado-García, C. A., Peñaranda, E. O., Puig, L., Meng, X., Fox, T., & Guana, A. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0521-z · Cited by 26
“These findings are similar to prior reports on the efficacy of secukinumab over 52 weeks and support the use of secukinumab in both subgroups at the preferred dose of 300 mg [3, 7].”
ResultZachariae, C. O. C., Gordon, K. B., Kimball, A. B., Lebwohl, M., Blauvelt, A., Leonardi, C. L., Braun, D., McKean-Matthews, M., Burge, R. T., & Cameron, G. S. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.03.047 · Cited by 27
Immunogenicity and skin clearance recapture in clinical studies of brodalumab
Bagel, J., Lebwohl, M., Israel, R. J., & Jacobson, A. A. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.05.094 · Cited by 26
Metadata
- Authors
- Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., Rivas, E., Tsai, T.-F., Wasel, N., Tyring, S., Salko, T., Hampele, I., Notter, M., Karpov, A., Helou, S., & Papavassilis, C.
- Affiliations
- Dalhousie University (CA)
- University of Alabama at Birmingham (US)
- Mount Sinai Hospital (US)
- Dermatologikum Hamburg (DE)
- Manchester Academic Health Science Centre (GB)
- Probity Medical Research (CA)
- Hospital de Sant Pau (ES)
- Jikei University School of Medicine (JP)
- University of Iceland (IS)
- National Taiwan University (TW)
- Center for Clinical Studies (US)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-24
- Volume
- 371
- Issue
- 4
- Pages
- 326-338
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1973354423
- Cited by
- 1,997
- References
- 25
- Citations by year
- 2026: 96 · 2025: 107 · 2024: 116 · 2023: 142 · 2022: 146 · 2021: 165 · 2020: 198 · 2019: 230 · 2018: 201 · 2017: 223 · 2016: 203 · 2015: 146 · 2014: 19
- FWCI
- 90.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (acceptedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- GRO (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- secukinumab, plaque psoriasis, IL-17A, anti-IL-17A monoclonal antibody, etanercept, PASI 75, dosing regimen, biologic therapy, treatment efficacy and safety, erasure, fixtures, Psoriasis Area and Severity Index
- MeSH terms
- Etanercept, Adult, Antibodies, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Immunoglobulin A, Immunoglobulin G, Immunosuppressive Agents, Infections, Injections, Subcutaneous, Male, Middle Aged, Psoriasis, Receptors, Tumor Necrosis Factor, Interleukin-17, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.